RET-targeting molecular stratified non-small-cell lung cancers.

ABSTRACT: Recent advances in lung cancer genomics have successfully characterized therapeutic targets of lung cancer. RET fusion gene products are among the newest target molecules for lung adenocarcinoma. Preclinical findings and preliminary reports regarding potential tumor control by RET-targeting multi-kinase inhibitors encourage further clinical trials. The infrequent prevalence of RET fusion gene-positive cases may be a major obstacle hindering the development of RET-targeted therapy. Thus, it is necessary to recruit appropriate participants for trials to develop an efficient RET fusion gene detection system to achieve targeted therapy for lung adenocarcinomas stratified by this molecular target.

SUBMITTER: Tsuchihara K 

PROVIDER: S-EPMC4367625 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature